This year, beauty technology company Cutera filed for a prepackaged Chapter 11 bankruptcy on March 5 to reduce its debt by ...

Hims & Hers Health recurring revenue grew 111% YoY, boosted by personalization and chronic care. Forecasting $2.35B revenue ...

Hims & Hers Health (HIMS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The overall sentiment of these big-money traders is split between 31% bullish and 50%, bearish. Out of all of the special options we uncovered, 3 are puts, for a total amount of $106,898, and 13 are ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

An article in The Journal For Nurse Practitioners found that Depo-Testosterone was the most cost-efficient TRT option, and ...

PUBLIC NOTICE Public Meeting Notice Goshen Irrigation District & HDR Engineering A public meeting will be held on Tuesday, July 22, at 6:00 p.m. at the Goshen County Rendezvous Center.

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ...

Hims reports that many men avoid doctor visits, worsening health. Erectile dysfunction (ED) can be a sign of serious issues, ...

Amazon's cloud arm, AWS, has slashed at least hundreds of jobs—including roles in specialist, training, certification, and ...

Joe Spector, founder of Dutch and Hims & Hers co-founder, joins us to discuss how telehealth is transforming pet care—and ...